LY-3475070
99%
- Product Code: 202782
CAS:
2375815-63-5
| Molecular Weight: | 286.34 g./mol | Molecular Formula: | C₁₅H₁₈N₄O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
LY-3475070 is a selective kappa opioid receptor (KOR) antagonist being investigated primarily for its potential in treating psychiatric and neurological disorders. It has shown promise in preclinical studies for modulating stress-related behaviors and depressive symptoms without the side effects commonly associated with traditional antidepressants. Due to its ability to cross the blood-brain barrier effectively, it is being explored as a therapeutic agent in mood disorders, including major depressive disorder and anxiety. Additionally, its KOR antagonism may help reduce dysphoria and anhedonia, making it a candidate for conditions involving reward pathway dysfunction. Research is ongoing to evaluate its efficacy in substance use disorders, where KOR activation plays a role in drug-seeking behavior and relapse. Its development highlights a targeted approach to mental health treatment with improved tolerability and faster onset of action.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | $413.28 |
+
-
|
| 25mg | 10-20 days | $1,051.71 |
+
-
|
| 100mg | 10-20 days | $3,038.47 |
+
-
|
LY-3475070
LY-3475070 is a selective kappa opioid receptor (KOR) antagonist being investigated primarily for its potential in treating psychiatric and neurological disorders. It has shown promise in preclinical studies for modulating stress-related behaviors and depressive symptoms without the side effects commonly associated with traditional antidepressants. Due to its ability to cross the blood-brain barrier effectively, it is being explored as a therapeutic agent in mood disorders, including major depressive disorder and anxiety. Additionally, its KOR antagonism may help reduce dysphoria and anhedonia, making it a candidate for conditions involving reward pathway dysfunction. Research is ongoing to evaluate its efficacy in substance use disorders, where KOR activation plays a role in drug-seeking behavior and relapse. Its development highlights a targeted approach to mental health treatment with improved tolerability and faster onset of action.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :